Today Jefferies Maintains a Buy Rating on Glaxosmithkline (LON:GSK) and a GBX 1730.00 Target Price

July 13, 2018 - By Benjamin Allen

GlaxoSmithKline plc (LON:GSK) Logo

Glaxosmithkline (LON:GSK) Rating Reaffirmed

Equity research analysts at Jefferies now has a GBX 1730.00 target on Glaxosmithkline (LON:GSK). Jefferies and their recent target means a potential upside of 9.77 % from the company’s last price. The rating has been disclosed to clients in an analyst note on Friday morning.

GlaxoSmithKline plc (LON:GSK) Ratings Coverage

Among 16 analysts covering GlaxoSmithKline PLC (LON:GSK), 7 have Buy rating, 1 Sell and 8 Hold. Therefore 44% are positive. GlaxoSmithKline PLC has GBX 2030 highest and GBX 1130 lowest target. GBX 1573’s average target is -0.19% below currents GBX 1576 stock price. GlaxoSmithKline PLC had 48 analyst reports since January 15, 2018 according to SRatingsIntel. On Monday, July 2 the stock rating was maintained by UBS with “Buy”. The firm earned “Reduce” rating on Monday, February 5 by Kepler Cheuvreux. The firm has “Hold” rating given on Tuesday, July 3 by Deutsche Bank. Barclays Capital maintained the shares of GSK in report on Friday, February 9 with “Overweight” rating. The company was maintained on Wednesday, March 28 by Deutsche Bank. The rating was maintained by Liberum Capital with “Buy” on Friday, February 9. HSBC maintained the stock with “Buy” rating in Wednesday, March 28 report. The stock of GlaxoSmithKline plc (LON:GSK) has “Hold” rating given on Friday, March 23 by Shore Capital. The stock has “Hold” rating by Deutsche Bank on Thursday, April 26. On Tuesday, January 30 the stock rating was maintained by Barclays Capital with “Overweight”.

The stock decreased 0.04% or GBX 0.6 during the last trading session, reaching GBX 1576. About 7.22M shares traded. GlaxoSmithKline plc (LON:GSK) has 0.00% since July 13, 2017 and is . It has underperformed by 12.57% the S&P500.

Analysts await GlaxoSmithKline plc (LON:GSK) to report earnings on July, 25. They expect $0.71 EPS, up 1.43 % or $0.01 from last year’s $0.7 per share. GSK’s profit will be $34.89 million for 554.93 P/E if the $0.71 EPS becomes a reality. After $0.68 actual EPS reported by GlaxoSmithKline plc for the previous quarter, Wall Street now forecasts 4.41 % EPS growth.

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company has market cap of 77.44 billion GBP. It operates through four divisions: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. It has a 75.41 P/E ratio. The firm offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.